Regulation of PGI2 activity by serum proteins: serum albumin but not high density lipoprotein is the PGI2 binding and stabilizing protein in human blood
- PMID: 1764464
- DOI: 10.1016/0304-4165(91)90021-8
Regulation of PGI2 activity by serum proteins: serum albumin but not high density lipoprotein is the PGI2 binding and stabilizing protein in human blood
Abstract
Although previous studies have shown that serum albumin binds PGI2 and protects it from rapid degradation, it remains debatable whether it is physiologically important due to its low binding affinity for PGI2. We were intrigued by the observations of Yui et al. (J. Clin. Invest. 82 (1988) 803-807) which suggested that apo A-I of the high density lipoprotein (HDL) is the "serum PGI2 stabilizing factor". To clarify this, we carried out experiments to determine the binding kinetics and parameters of HDL and albumin purified from normal pooled human serum. Despite the use of multiple binding assays, we could not detect any binding activity in HDL2, HDL3 or nascent HDL preparations, nor could we demonstrate any PGI2 protecting activity by these molecules. By contrast, purified albumin exhibited essentially identical binding parameters as the native serum from which the albumin was purified. The binding activity of various albumin preparations was not due to the contamination of apo A-I. Computer simulation analysis also failed to provide evidence to support the notion that HDL bound and prolonged PGI2 activity. To determine whether physiological concentrations of albumin influence PGI2 binding to platelet receptors, we measured PGI2 binding to platelet membrane in the absence and presence of albumin. Albumin at 40 mg/ml increased the KD of PGI2 binding to the receptors by 2-3 fold. These findings indicate that albumin plays a major role in protecting PGI2 activity and regulating its availability for platelet PGI2 receptors.
Similar articles
-
Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I). A novel function of Apo A-I.J Clin Invest. 1988 Sep;82(3):803-7. doi: 10.1172/JCI113682. J Clin Invest. 1988. PMID: 3047170 Free PMC article.
-
Prostaglandin I2 half-life regulated by high density lipoprotein is decreased in acute myocardial infarction and unstable angina pectoris.Circulation. 1990 Jun;81(6):1784-91. doi: 10.1161/01.cir.81.6.1784. Circulation. 1990. PMID: 2111741
-
Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors.Br J Pharmacol. 1989 Jul;97(3):657-68. doi: 10.1111/j.1476-5381.1989.tb12001.x. Br J Pharmacol. 1989. PMID: 2474350 Free PMC article.
-
Modulation of vascular thrombosis by products of arachidonic acid metabolism.Clin Physiol Biochem. 1984;2(2-3):84-90. Clin Physiol Biochem. 1984. PMID: 6435930 Review.
-
PGI2-receptors and molecular mechanisms in platelets and vasculature: state of the art.Pharmacol Res Commun. 1987 Nov;19(11):735-65. doi: 10.1016/0031-6989(87)90010-5. Pharmacol Res Commun. 1987. PMID: 3328202 Review. No abstract available.
Cited by
-
Anticoagulant action of low, physiologic, and high albumin levels in whole blood.PLoS One. 2017 Aug 11;12(8):e0182997. doi: 10.1371/journal.pone.0182997. eCollection 2017. PLoS One. 2017. PMID: 28800610 Free PMC article.
-
Blood plasma influences anti-aggregatory potency of prostaglandins: effect of albumin.Inflammopharmacology. 1999;7(2):179-85. doi: 10.1007/BF02918389. Inflammopharmacology. 1999. PMID: 18597158
-
Fibrinogen Albumin Ratio and Ischemic Stroke During Venoarterial Extracorporeal Membrane Oxygenation.ASAIO J. 2020 Mar;66(3):277-282. doi: 10.1097/MAT.0000000000000992. ASAIO J. 2020. PMID: 30973402 Free PMC article.
-
Gene therapy for vascular diseases.Tex Heart Inst J. 1994;21(1):98-103. Tex Heart Inst J. 1994. PMID: 8180517 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources